Premium
Prevalence of Elevated Troponin I in End‐stage Renal Disease Patients Receiving Hemodialysis
Author(s) -
Donnino Michael W.,
KarriemNorwood Varnada,
Rivers Emanuel P.,
Gupta Ajay,
Nguyen H. Bryant,
Jacobsen Gordon,
McCord James,
Tomlanovich Michael C.
Publication year - 2004
Publication title -
academic emergency medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.221
H-Index - 124
eISSN - 1553-2712
pISSN - 1069-6563
DOI - 10.1197/j.aem.2004.03.022
Subject(s) - medicine , troponin i , hemodialysis , end stage renal disease , asymptomatic , dialysis , cardiology , prospective cohort study , incidence (geometry) , myocardial infarction , physics , optics
Objectives: Patients with end‐stage renal disease (ESRD) who are receiving hemodialysis have an increased incidence of atherosclerotic heart disease. Currently, there is considerable controversy regarding the significance of elevated cardiac troponin I (cTnI) levels in patients with ESRD. The objective of this study was to examine the prevalence of elevated cTnI levels in asymptomatic patients with ESRD on hemodialysis. Methods: This was a prospective cohort study at an urban hospital outpatient dialysis center. Serum was collected pre‐ and postdialysis from patients on dialysis at this center over a two‐week period. Samples were batched and analyzed for cTnI using the Asxym fluorescent antibody test. An elevated cTnI level was defined as >0.8 ng/dL. Results: Predialysis cTnI levels ranged from <0.1 to 0.7 ng/dL, and postdialysis cTnI levels ranged from <0.1 to 0.6 ng/dL. None of the patients had a cTnI level >0.8 ng/dL. Conclusions: cTnI levels are not falsely elevated in patients with ESRD on hemodialysis. In a patient with ESRD, myocardial injury should be suspected if his or her cTnI level is >0.8 ng/dL.